authors
- De Vries, TI
- Eikelboom, John
- Bosch, Jackie
- Westerink, J
- Dorresteijn, JAN
- Alings, M
- Dyal, L
- Berkowitz, SD
- Van der Graaf, Y
- Fox, KAA
- Visseren, FLJ
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial
Conferences
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- October 1, 2019
has subject area
- 1102 Cardiorespiratory Medicine and Haematology (FoR)
- 1103 Clinical Sciences (FoR)
- Cardiovascular System & Hematology (Science Metrix)
published in
- European Heart Journal Journal